| Field | Summary | Suggested ontology/identifier(s) | Evidence |
|---|---|---|---|
| Scope / definition | Autosomal recessive progressive external ophthalmoplegia 1 is best resolved here as a POLG-related adult/late-onset mitochondrial disease phenotype within the broader POLG disorder spectrum, characterized by progressive weakness of extraocular muscles causing ptosis and ophthalmoparesis; it is distinct from dominant POLG PEO and from PEO caused by TWNK, RNASEH1, TK2, RRM2B, or primary mtDNA defects. | OMIM phenotype name: Autosomal recessive progressive external ophthalmoplegia 1; disease label also reported as arPEO / POLG-related arPEO. | (pqac-00000000, pqac-00000002, pqac-00000004, pqac-00000009) |
| OMIM identifier | OMIM 258450 was explicitly associated with autosomal recessive progressive external ophthalmoplegia in the gathered evidence. | OMIM: 258450 | (pqac-00000000) |
| Likely MONDO mapping caveat | A MONDO term was not verified in the gathered evidence. If a MONDO mapping is added downstream, it should be manually checked because PEO entities are genetically heterogeneous and MONDO may group phenotype-level and gene-level concepts differently. | MONDO: not verified from gathered sources | (pqac-00000000, pqac-00000002) |
| Causal gene / protein | Causal gene: POLG, encoding the catalytic subunit of mitochondrial DNA polymerase gamma (DNA polymerase γA / POLγA), the only mitochondrial DNA polymerase responsible for mtDNA replication and repair. | Gene: POLG; Protein: DNA polymerase subunit gamma-1 / POLγA; HGNC/NCBI Gene IDs not verified from gathered sources | (pqac-00000000, pqac-00000005, pqac-00000013) |
| Inheritance | Autosomal recessive; usually biallelic pathogenic germline variants, often compound heterozygous, though homozygous A467T cases occur. Yeast modeling of the A467T-analog supports recessive behavior. | Inheritance: autosomal recessive; germline | (pqac-00000000, pqac-00000003, pqac-00000012) |
| Hallmark phenotypes | Core phenotype: progressive external ophthalmoplegia/ophthalmoparesis with bilateral ptosis; early subtle slowed/incomplete saccades may occur. Additional POLG-associated “PEO-plus” features can include limb weakness, bulbar involvement, exercise intolerance, peripheral neuropathy, ataxia, hearing loss, tremor, seizures, and other multisystem manifestations, but these are not specific to arPEO1 alone. | HPO suggestions: Ptosis (HP:0000508, verified code not checked here), External ophthalmoplegia / Ophthalmoparesis (code not verified), Exercise intolerance (code not verified), Peripheral neuropathy (code not verified), Ataxia (code not verified), Sensorineural hearing impairment (code not verified), Tremor (code not verified), Seizure (code not verified) | (pqac-00000001, pqac-00000002, pqac-00000007, pqac-00000009) |
| Common pathogenic variant themes | Recurrent POLG variants in broader POLG disease include A467T, W748S, G848S, and T251I-P587L; A467T is the most common disease-associated allele in Europeans and functionally recessive. W748S commonly occurs in cis with E1143G, which can modify severity. Variant-level pathogenic classifications were not systematically verified from ClinVar in gathered evidence. | Variant examples: A467T; W748S; G848S; T251I-P587L; E1143G modifier/polymorphic context | (pqac-00000003, pqac-00000004, pqac-00000005, pqac-00000006) |
| Mechanism / pathophysiology | Upstream defect: impaired POLγ-mediated mtDNA replication/maintenance. A467T reduces polymerase activity to ~4% of wild type and disrupts interaction with the POLG2 accessory subunit; W748S reduces catalytic activity/processivity and impairs DNA binding. Downstream consequences include multiple mtDNA deletions and sometimes mtDNA depletion, leading to respiratory-chain dysfunction in high-energy tissues such as extraocular muscle, skeletal muscle, and nervous system. | GO suggestions: mitochondrial DNA replication (GO code not verified), DNA repair (GO code not verified), oxidative phosphorylation (GO code not verified), mitochondrial genome maintenance (GO code not verified) | (pqac-00000001, pqac-00000004, pqac-00000005, pqac-00000013) |
| Tissues / cells / compartments affected | Primary tissues: extraocular muscles and skeletal muscle; broader involvement can include peripheral and central nervous system, liver, and heart in the wider POLG spectrum. Cell populations likely implicated include skeletal muscle fibers and neurons, but exact CL terms were not verified. Key compartment: mitochondrion, especially mtDNA nucleoid/mitochondrial matrix replication machinery. | UBERON suggestions: extraocular muscle (code not verified), skeletal muscle tissue (code not verified), peripheral nerve (code not verified), brain (code not verified); CL suggestions: skeletal muscle cell / myofiber, neuron (codes not verified); GO cellular component suggestions: mitochondrion, mitochondrial matrix, mitochondrial nucleoid (codes not verified) | (pqac-00000000, pqac-00000002, pqac-00000009) |
| Diagnostic signature | Diagnostic clues include progressive bilateral ptosis and ophthalmoparesis, often adult onset, with muscle biopsy frequently showing mitochondrial myopathy changes such as ragged-red/COX-negative fibers and molecular evidence of multiple mtDNA deletions; CK may be normal or elevated in broader PEO cohorts. Genetic confirmation relies on sequencing of POLG (now often via exome/genome/panel testing); muscle biopsy remains highly informative in broader mitochondrial PEO when etiology is uncertain. | Diagnostic modalities: POLG sequencing; mtDNA deletion analysis in muscle; muscle biopsy; WES/WGS/panel testing. Biomarker codes not verified. | (pqac-00000001, pqac-00000007, pqac-00000008, pqac-00000009) |
| Treatment / prevention | No disease-modifying therapy was identified. Current care is supportive: ptosis aids/crutches, ptosis surgery (levator procedures or frontalis suspension), prism or strabismus surgery if diplopia/strabismus occur, rehabilitation/exercise as tolerated, and multidisciplinary surveillance for extraocular and systemic complications. In the broader POLG spectrum, valproate is contraindicated because of risk of liver failure. Prevention is mainly reproductive/genetic: genetic counseling, carrier/family testing, and consideration of prenatal or preimplantation testing where appropriate. | NCIT suggestions: genetic counseling, ptosis surgery, strabismus surgery, physical therapy / rehabilitation (codes not verified); Prevention: cascade testing, prenatal diagnosis, PGT (codes not verified) | (pqac-00000007, pqac-00000010) |
| Epidemiology / frequency | Disease-specific prevalence for arPEO1 was not found in gathered evidence. For a major recurrent allele, A467T carrier frequency was reported around 0.2–0.3% in mixed European populations, up to 1.3–1.4% in Belgian/British populations, with predicted homozygote prevalence ~1 in 500,000 to 1,000,000; these figures describe a variant, not arPEO1 prevalence. | Epidemiology for disease: not established from gathered sources | (pqac-00000003, pqac-00000005) |
| Model systems / translational evidence | Yeast MIP1 models reproduce recessive behavior and mtDNA instability of human POLG variants; the A467T-analog behaves as a mild recessive defect in diploids. Broader POLG mutator mice model mtDNA deletion-driven mitochondrial dysfunction and premature aging, but no model perfectly recapitulates human POLG disease. Patient fibroblast and biochemical assays support defective holoenzyme assembly and replication failure. | Model classes: yeast, mouse, patient fibroblasts, biochemical enzyme assays | (pqac-00000011, pqac-00000012, pqac-00000013, pqac-00000018) |
| Key evidence limitations | Much evidence is for the broader POLG spectrum or heterogeneous mitochondrial PEO cohorts rather than arPEO1 alone. Verified MONDO/HPO/GO/CL/UBERON/HGNC codes were not directly retrieved in the gathered sources and should not be auto-filled without ontology lookup. No arPEO1-specific interventional trial, single-cell/spatial omics profile, validated protective factor, or robust natural-history epidemiology study was identified in gathered evidence. | Limitation flags: ontology IDs unverified; arPEO1-specific trials absent in gathered evidence | (pqac-00000002, pqac-00000009, pqac-00000010, pqac-00000018) |


*Table: This table condenses the key knowledge-base fields for autosomal recessive progressive external ophthalmoplegia 1 as supported by the gathered POLG-related evidence. It highlights what is well supported, what is broader-spectrum rather than arPEO1-specific, and which ontology identifiers still require external verification.*